These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30097236)

  • 1. Immune check-point in cervical cancer.
    De Felice F; Marchetti C; Palaia I; Ostuni R; Muzii L; Tombolini V; Benedetti Panici P
    Crit Rev Oncol Hematol; 2018 Sep; 129():40-43. PubMed ID: 30097236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy in patients with preexisting autoimmune disorders.
    Donia M; Pedersen M; Svane IM
    Semin Immunopathol; 2017 Apr; 39(3):333-337. PubMed ID: 27730287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
    Bose CK
    Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.
    Dyer BA; Zamarin D; Eskandar RN; Mayadev JM
    J Natl Compr Canc Netw; 2019 Jan; 17(1):91-97. PubMed ID: 30659133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection.
    Banna GL; Passiglia F; Colonese F; Canova S; Menis J; Addeo A; Russo A; Cortinovis DL
    Crit Rev Oncol Hematol; 2018 Sep; 129():27-39. PubMed ID: 30097235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
    Loo K; Daud AI
    Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current status of checkpoint inhibitors in metastatic bladder cancer.
    Fahmy O; Khairul-Asri MG; Stenzl A; Gakis G
    Clin Exp Metastasis; 2016 Oct; 33(7):629-35. PubMed ID: 27380916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM; Carvajal RD
    Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
    Spain L; Larkin J
    Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
    [No Abstract]   [Full Text] [Related]  

  • 10. The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer.
    Otter SJ; Chatterjee J; Stewart AJ; Michael A
    Clin Oncol (R Coll Radiol); 2019 Dec; 31(12):834-843. PubMed ID: 31331818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Di Nunno V; De Luca E; Buttigliero C; Tucci M; Vignani F; Gatto L; Zichi C; Ardizzoni A; Di Maio M; Massari F
    Crit Rev Oncol Hematol; 2018 Sep; 129():124-132. PubMed ID: 30097230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D in melanoma: Controversies and potential role in combination with immune check-point inhibitors.
    Stucci LS; D'Oronzo S; Tucci M; Macerollo A; Ribero S; Spagnolo F; Marra E; Picasso V; Orgiano L; Marconcini R; De Rosa F; Di Guardo L; Galli G; Gandini S; Palmirotta R; Palmieri G; Queirolo P; Silvestris F;
    Cancer Treat Rev; 2018 Sep; 69():21-28. PubMed ID: 29864718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.
    La-Beck NM; Jean GW; Huynh C; Alzghari SK; Lowe DB
    Pharmacotherapy; 2015 Oct; 35(10):963-76. PubMed ID: 26497482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer.
    Hashemi-Sadraei N; Sikora AG; Brizel DM
    Am Soc Clin Oncol Educ Book; 2016; 35():e277-82. PubMed ID: 27249733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Checkpoint inhibitors: outstanding efficacy but at what cost?
    Klastersky JA
    Curr Opin Oncol; 2016 Jul; 28(4):253. PubMed ID: 27163724
    [No Abstract]   [Full Text] [Related]  

  • 18. Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
    Carbonnel F; Soularue E; Coutzac C; Chaput N; Mateus C; Lepage P; Robert C
    Semin Immunopathol; 2017 Apr; 39(3):327-331. PubMed ID: 28093620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
    Kfoury M; Disdero V; Vicier C; Le Saux O; Gougis P; Sajous C; Vignot S
    Bull Cancer; 2018; 105(7-8):686-695. PubMed ID: 29933886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.